As a pathologist, I do not see patients directly, as you know, but just based on the number of phone calls I get from the medical oncologists and their increasing interest in these biomarkers, I think this is their bread and butter. I really think this is the standard of care. I think that as we learn more about lung cancers, we are only going to see more and more drugs in targeted therapy and biomarkers as companion diagnostic tests.
I mentioned previously—and I submitted this in my brief—that if you think of one of those pie charts, we know the type of oncogenic drivers for about 54% or 55% of lung adenocarcinomas. We have the other 46% or 45% to research, and hopefully we can identify biomarkers and drugs that will really work for the patients—and not only in improving their overall survival, but also their quality of life. Indeed, without actually seeing the patients every day, what's important to me is their quality of life. I have learned from my medical oncologist colleagues that they no longer send their patients home by saying, “I'm sorry, but there is nothing I can offer you.” They can actually say to their patients that they can go home with an oral pill, they can swallow that particular pill for several months, and their prognosis and quality of life will be better. They can say, “We know you're going to live longer with your disease.”